| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7553835 | MYLAN | Topical antifungal composition |
Oct, 2018
(5 years ago) | |
| US8026238 | MYLAN | Topical antifungal composition |
Oct, 2018
(5 years ago) | |
Extina is owned by Mylan.
Extina contains Ketoconazole.
Extina has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Extina are:
- US7553835
- US8026238
Extina was authorised for market use on 12 June, 2007.
Extina is available in aerosol, foam;topical dosage forms.
Extina can be used as topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older, treatment of seborrhea dermatitis in humans.
The generics of Extina are possible to be released after 19 October, 2018.
Drugs and Companies using KETOCONAZOLE ingredient
Market Authorisation Date: 12 June, 2007
Treatment: Treatment of seborrhea dermatitis in humans; Topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older
Dosage: AEROSOL, FOAM;TOPICAL
EXTINA family patents
